NCT06452745 Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile
| NCT ID | NCT06452745 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Investigacio Sanitaria Pere Virgili |
| Condition | Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2019-07-20 |
| Primary Completion | 2030-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2019-07-20 with a primary completion date of 2030-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Colorectal cancer is the most frequent tumor in our environment if both sexes are considered together. Every year almost 800 cases are diagnosed in the districts of Tarragona. A little more than half of colorectal cancers are cured with surgery, with or without the addition of complementary treatments with chemotherapy and/or radiation therapy. Those who are not cured is because at the time of diagnosis the disease has already spread or they spread after having been treated surgically with curative intent. The purpose of the EarlyCRC project is to determine whether metabolites (substances of low molecular weight) can be found in the urine and stool of patients with colorectal cancer or polyps that can be easily and cheaply differentiated (urine or stool analysis) between the patients affected by colorectal cancer or polyps, from healthy individuals. For the identification of these possible metabolites, the urine analysis will be performed using the usual techniques in metabolomics, which studies the existing metabolites in biological processes.
Eligibility Criteria
Inclusion Criteria: * Patients with a positive FOBT test result from the Colorectal Cancer Early Detection Program and referred for a colonoscopy. Exclusion Criteria: * Patients diagnosed with another primary neoplasm in the last 5 years, with the exception of carcinoma in situ of the cervix or non-melanoma skin cancer. * Patients with severe kidney disease stage IV (creatinine clearance \< 30 ml/min). * Patients with severe active liver disease (hepatitis, cirrhosis). * Refusal to sign informed consent.
Frequently Asked Questions
Who can join the NCT06452745 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 70 Years, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06452745 currently recruiting?
Yes, NCT06452745 is actively recruiting participants. Visit ClinicalTrials.gov or contact Institut Investigacio Sanitaria Pere Virgili to inquire about joining.
Where is the NCT06452745 trial being conducted?
This trial is being conducted at Reus, Spain, Tarragona, Spain.
Who is sponsoring the NCT06452745 clinical trial?
NCT06452745 is sponsored by Institut Investigacio Sanitaria Pere Virgili. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.